Issue Archive

Associate Editors Hendrickson and Ortel edited a How I Treat series on inpatient consultative hematology. In this timely series of articles, the authors present an approach to bleeding, thrombosis, anemia, and quantitative neutrophil abnormalities.

Associate Editors Hendrickson and Ortel edited a How I Treat series on inpatient consultative hematology. In this timely series of articles, the authors present an approach to bleeding, thrombosis, anemia, and quantitative neutrophil abnormalities.

Associate Editors Hendrickson and Ortel edited a How I Treat series on inpatient consultative hematology. In this timely series of articles, the authors present an approach to bleeding, thrombosis, anemia, and quantitative neutrophil abnormalities.

Associate Editors Hendrickson and Ortel edited a How I Treat series on inpatient consultative hematology. In this timely series of articles, the authors present an approach to bleeding, thrombosis, anemia, and quantitative neutrophil abnormalities.

Associate Editors Hendrickson and Ortel edited a How I Treat series on inpatient consultative hematology. In this timely series of articles, the authors present an approach to bleeding, thrombosis, anemia, and quantitative neutrophil abnormalities.

Cutaneous T-cell lymphoma (CTCL) is a challenging disease with limited targeted therapies or curative approaches. Nicolay et al report on a phase 2 study of dimethyl fumarate (DMF), which is known to inhibit NF-κB in CTCL lymphocytes, in 25 patients with stage Ib-IV CTCL. DMF is well tolerated, and 30% of patients have skin responses, with best responses in patients with high skin tumor burden. However, responses in the blood are limited. DMF is a well-tolerated targeted therapy that should be investigated further, probably in combination with other therapies.

Female survivors of Hodgkin lymphoma (HL) treated with chest radiation have a markedly increased risk of subsequent breast cancer. de Vries and colleagues report that male survivors of HL who receive chest radiation also have a 23-fold increased rate of breast cancer, although the absolute incidence remains low. Nevertheless, these data suggest that clinicians should be aware of the possible development of male breast cancer after treatment for HL.

Ex vivo gene editing in T cells and hematopoietic stem/progenitor cells (HSPCs) involves delivery of the editing machinery via electroporation. Electroporation and gene editing cause cytotoxicity in T cells and activate a DNA damage response in HSPCs. Vavassori et al report that delivering vectors by lipid nanoparticles (LNPs) reduces cell death, improves cell growth, and improves HSPC clonogenic activity in repopulation assay, suggesting that LNPs may improve efficiency and reduce toxicity of ex vivo gene editing.

The nuclear factor of activated T cells (NFAT) family of transcription factors is important for immunity in murine models, but their role in human immune function is unknown. Kostel Bal et al analyzed 3 members of a family pedigree with germ line biallelic missense mutations in NFATC1 presenting with recurrent infections, hypogammaglobulinemia, and decreased antibody responses. The authors demonstrate a defect in T-cell activation arising from defective glycolysis that is partially compensated by enhanced lipid metabolism.

Casey and colleagues examined health disparities in clinical trials in lymphoma. By comparing the demographic and geographic diversity of the populations represented in randomized clinical trials to the US census population reflected in the National Cancer Institute Surveillance, Epidemiology, and End Results Program database, the authors confirmed that there are significant health disparities in clinical trial enrollment that may have an impact on translating clinical trial results to the “real world” US population of patients with lymphoma.